Safety and Pharmacokinetics of VNRX-5133 in the Epithelial Lining Fluid of Healthy Adult Subjects

NCT03870490 | Completed Phase 1 FDA Drug

• 3 other identifiers: VNRX-5133-106272201300019C-17-0-318-0001
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

This is a single-center, open-label study to assess safety and pharmacokinetics of VNRX-5133 and cefepime in the epithelial lining fluid in healthy adult male and female subjects.

Conditions

Healthy Subjects

Outcome Measures

Primary Outcomes (2)

• Pharmacokinetics (PK) in Epithelial Lining Fluid (ELF)

  Steady-state plasma PK and disposition of cefepime/VNRX-5133 in the ELF

  Day 2

• Safety as measured by the number of subjects with adverse events

  Number of Subjects with AEs (Assessed via patient report, physical exam, ECGs, vital signs, laboratory investigations, and use of concomitant medications for the treatment of AEs)

  Days 1-7

Study Arms (1)

Healthy Subjects

EXPERIMENTAL

VNRX-5133 + cefepime

Drug: VNRX-5133 + cefepime

Interventions

VNRX-5133 + cefepime DRUG

IV infusion (3 doses)

Healthy Subjects

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Willing to participate in the trial, give written informed consent, and comply with the trial restrictions
• Gender: male or female with a negative serum pregnancy test (β-human chorionic gonadotropin \[β-hCG\]) at Screening and Day -1; females may be of childbearing potential or of nonchildbearing potential
• Age: ≥18 years at Screening
• Weight: ≥50 kg
• Body mass index (BMI): ≥18 kg/m2 and \<30 kg/m2
• Normal blood pressure (BP), defined as a systolic value ≥90 mm Hg and ≤140 mm Hg and a diastolic value \<90 mm Hg (Screening and Day -1)
• All values for hematology and clinical chemistry tests of blood and urine are either within normal limits of laboratory reporting range (WNL) or defined as permitted exceptions
• Ability and willingness to abstain from alcohol, from 48 hours (2 days) prior to admission to the Clinical Research Center (CRC) until discharge from the CRC
• Males who are not surgically sterilized and females of childbearing potential must agree to use highly effective methods of contraception during this trial and for 90 days after the last dose of study drug
• All over-the-counter (OTC) medications, health supplements, and herbal remedies (eg, St. John's Wort extract) must have been stopped at least 14 days prior to admission to the CRC
• Suitable veins for cannulation/multiple venipunctures as assessed by the Investigator at Screening

You may not qualify if:

• Employee of the Contract Research Organization (CRO), CRC, or the Sponsor
• Female who is pregnant, lactating, or at risk of becoming pregnant during this trial or within 90 days after the last dose of study drug
• Male with a female partner who is pregnant or lactating during this trial or planning to attempt to become pregnant during this trial or within 90 days after the last dose of study drug
• Use of any investigational drug or device within 30 days prior to Screening (90 days for an injectable biological agent)
• Presence of a congenital or acquired immunodeficiency syndrome
• Any evidence or history of clinically significant medical abnormalities on PE or laboratory assessment
• Clinically significant ECG abnormality
• Sitting systolic BP \>140 mm Hg or diastolic BP \>90 mm Hg on a single measurement following at least 5 minutes of rest at Screening
• History of drug allergy of a severity that required urgent medical treatment such as treatment with epinephrine in an Emergency Department
• History of any hypersensitivity reaction following administration of a cephalosporin, penicillin, or other β-lactam antibacterial drug or any component of VNRX-5133 for injection formulation
• History of hypersensitivity to lidocaine, midazolam, fentanyl, or other topical anesthetics/opioids in similar classes to these agents
• Use of prescription or nonprescription drugs, vitamins, or dietary supplements within 14 days prior to the first dose of study drug
• History of donation of \>450 mL of blood within 60 days prior to first dose of study drug or planned donation before 30 days has elapsed since final dose of study drug
• Plasma or platelet donation within 7 days of first dose of study drug or planned donation during this trial
• Current suspected drug or alcohol abuse as specified in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision criteria

Sponsors & Collaborators

• Venatorx Pharmaceuticals, Inc.: lead
• National Institutes of Health (NIH): collaborator

Study Sites (1)

Hartford Hospital

Hartford, Connecticut, 06102, United States

Location

MeSH Terms

Interventions

taniborbactam; Cefepime

Intervention Hierarchy (Ancestors)

Cephalosporins; beta-Lactams; Lactams; Amides; Organic Chemicals; Thiazines; Sulfur Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 8, 2019
• First Posted: March 12, 2019
• Study Start: March 14, 2019
• Primary Completion: April 1, 2019
• Study Completion: April 1, 2019
• Last Updated: May 6, 2019

Record last verified: 2019-05

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)